(Q37194749)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

Karolina Andersson Sundell

9 January 2020

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Lars L. Gustafsson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1

Björn Wettermark

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

5

Alan Haycox

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

6

Vittorio Bertele

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

537-550

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

Current national initiatives about drug policies and cost control in Europe: the Italy example.

9 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200826070-00001

Endpoints in studies on myocardial infarction

21 January 2018

1 reference

12 December 2020

The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness

1 reference

12 December 2020

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.

1 reference

12 December 2020

National Institute for Clinical Excellence and its value judgments

1 reference

12 December 2020

Quality Incentives: The Case Of U.K. General Practitioners

1 reference

12 December 2020

Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.

1 reference

12 December 2020

Drug utilisation 90% profiles--a useful tool for quality assessment of prescribing in primary health care in Stockholm

1 reference

12 December 2020

How can we regulate medicines better?

1 reference

12 December 2020

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

1 reference

12 December 2020

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies

1 reference

12 December 2020

Experts disagree over NICE's approach for assessing drugs.

1 reference

12 December 2020

"Academic drug-detailing": from project to practice in a Swedish urban area

1 reference

12 December 2020

How much will Herceptin really cost?

1 reference

12 December 2020

The drug budget silo mentality: the French case

1 reference

12 December 2020

Pricing and reimbursement of drugs in Sweden.

1 reference

12 December 2020

Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription--a multilevel methodological approach

1 reference

12 December 2020

Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?

1 reference

12 December 2020

What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden

1 reference

12 December 2020

The costs and benefits of regulations for reimbursement of new drugs

1 reference

12 December 2020

Swedish healthcare under pressure

1 reference

12 December 2020

Fixed budgets as a cost containment measure for pharmaceuticals

1 reference

12 December 2020

Educational outreach visits: effects on professional practice and health care outcomes

1 reference

12 December 2020

Pharmaceutical policies: effects of financial incentives for prescribers

1 reference

12 December 2020

A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists

1 reference

12 December 2020

Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects

1 reference

12 December 2020

Effluent from drug manufactures contains extremely high levels of pharmaceuticals.

1 reference

12 December 2020

Why did drug spending increase during the 1990s? A decomposition based on Swedish data.

1 reference

12 December 2020

[Quality indicators for drug prescribing--the situation in Sweden]

1 reference

12 December 2020

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures

1 reference

12 December 2020

Janus computerised prescribing system provides pharmacological knowledge at point of care – design, development and proof of concept

1 reference

12 December 2020

NICE appraisals should be everybody's business

1 reference

12 December 2020

Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective

1 reference

12 December 2020

The increasingly complex fourth hurdle for pharmaceuticals

1 reference

12 December 2020

Non-inferiority trials are unethical because they disregard patients' interests

1 reference

12 December 2020

10.2165/00019053-200826070-00001

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 January 2020

1023372669

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18563945%20AND%20SRC:MED&resulttype=core&format=json